AU2020266956B2 - Crystal form of Wee1 inhibitor compound and use thereof - Google Patents
Crystal form of Wee1 inhibitor compound and use thereof Download PDFInfo
- Publication number
- AU2020266956B2 AU2020266956B2 AU2020266956A AU2020266956A AU2020266956B2 AU 2020266956 B2 AU2020266956 B2 AU 2020266956B2 AU 2020266956 A AU2020266956 A AU 2020266956A AU 2020266956 A AU2020266956 A AU 2020266956A AU 2020266956 B2 AU2020266956 B2 AU 2020266956B2
- Authority
- AU
- Australia
- Prior art keywords
- crystal form
- formula
- compound
- pattern
- ray powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910364694 | 2019-04-30 | ||
| CN201910364694.X | 2019-04-30 | ||
| PCT/CN2020/088451 WO2020221358A1 (zh) | 2019-04-30 | 2020-04-30 | Wee1抑制剂化合物的晶型及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2020266956A1 AU2020266956A1 (en) | 2021-10-28 |
| AU2020266956B2 true AU2020266956B2 (en) | 2025-05-08 |
Family
ID=73029676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020266956A Active AU2020266956B2 (en) | 2019-04-30 | 2020-04-30 | Crystal form of Wee1 inhibitor compound and use thereof |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US12291536B2 (https=) |
| EP (1) | EP3964510B1 (https=) |
| JP (1) | JP7582970B2 (https=) |
| CN (1) | CN113784968B (https=) |
| AU (1) | AU2020266956B2 (https=) |
| BR (1) | BR112021021230A8 (https=) |
| CA (1) | CA3138240C (https=) |
| DK (1) | DK3964510T3 (https=) |
| ES (1) | ES2984617T3 (https=) |
| FI (1) | FI3964510T3 (https=) |
| HR (1) | HRP20241008T1 (https=) |
| HU (1) | HUE068061T2 (https=) |
| IL (1) | IL287472A (https=) |
| LT (1) | LT3964510T (https=) |
| PL (1) | PL3964510T3 (https=) |
| PT (1) | PT3964510T (https=) |
| RS (1) | RS65747B1 (https=) |
| SG (1) | SG11202111315XA (https=) |
| SI (1) | SI3964510T1 (https=) |
| SM (1) | SMT202400303T1 (https=) |
| WO (1) | WO2020221358A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023217201A2 (zh) * | 2022-05-10 | 2023-11-16 | 杭州德睿智药科技有限公司 | 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008133866A1 (en) * | 2007-04-25 | 2008-11-06 | Merck & Co., Inc. | Polymorph of dihydropyrazolopyrimidinone derivative as weel kinase.inhibitor |
| CN108623615A (zh) * | 2017-03-23 | 2018-10-09 | 上海迪诺医药科技有限公司 | 吡唑[3,4-d]嘧啶-3-酮的大环衍生物、其药物组合物及应用 |
| WO2019085933A1 (zh) * | 2017-11-01 | 2019-05-09 | 南京明德新药研发股份有限公司 | 作为Wee1抑制剂的大环类化合物及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7163939B2 (en) * | 2003-11-05 | 2007-01-16 | Abbott Laboratories | Macrocyclic kinase inhibitors |
| PE20080695A1 (es) | 2006-04-27 | 2008-06-28 | Banyu Pharma Co Ltd | Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel |
| CA2667345C (en) * | 2006-10-27 | 2016-03-22 | Signal Pharmaceuticals, Llc | Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and uses therewith |
| WO2009054332A1 (ja) | 2007-10-23 | 2009-04-30 | Banyu Pharmaceutical Co., Ltd. | ピリドン置換ジヒドロピラゾロピリミジノン誘導体 |
| EP2477628B1 (en) | 2009-09-15 | 2014-08-20 | Merck Sharp & Dohme Corp. | Preparation of crystalline hemihydrate forms of dihydropyrazolopyrimidinone |
| TWI532742B (zh) | 2011-02-28 | 2016-05-11 | 艾伯維有限公司 | 激酶之三環抑制劑 |
| WO2013012681A1 (en) | 2011-07-15 | 2013-01-24 | Abbott Laboratories | Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases |
| US8796289B2 (en) | 2011-07-19 | 2014-08-05 | Abbvie Inc. | Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases |
| US9181239B2 (en) | 2011-10-20 | 2015-11-10 | Abbvie Inc. | Pyridopyrimidinone inhibitors of kinases |
| MX2014010176A (es) | 2012-02-23 | 2014-11-10 | Abbvie Inc | Inhibidores de cinasas de piridopirimidinona. |
| GB201306610D0 (en) | 2013-04-11 | 2013-05-29 | Almac Discovery Ltd | Pharmaceutical compounds |
| WO2015019037A1 (en) | 2013-08-05 | 2015-02-12 | Almac Discovery Limited | Pharmaceutical compounds |
| GB201322602D0 (en) | 2013-12-19 | 2014-02-05 | Almac Discovery Ltd | Pharmaceutical compounds |
| JP6692423B2 (ja) | 2015-11-01 | 2020-05-13 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト | Ｗｅｅ１キナーゼ阻害剤、並びにそれを作製及び使用する方法 |
| US12180184B2 (en) | 2018-10-26 | 2024-12-31 | Wuxi Biocity Biopharmaceutics Co., Ltd. | Pyrimidopyrazolone derivative as Wee1 inhibitor and use thereof |
-
2020
- 2020-04-30 SI SI202030468T patent/SI3964510T1/sl unknown
- 2020-04-30 US US17/607,447 patent/US12291536B2/en active Active
- 2020-04-30 WO PCT/CN2020/088451 patent/WO2020221358A1/zh not_active Ceased
- 2020-04-30 AU AU2020266956A patent/AU2020266956B2/en active Active
- 2020-04-30 HR HRP20241008TT patent/HRP20241008T1/hr unknown
- 2020-04-30 CN CN202080031816.4A patent/CN113784968B/zh active Active
- 2020-04-30 PT PT207989245T patent/PT3964510T/pt unknown
- 2020-04-30 EP EP20798924.5A patent/EP3964510B1/en active Active
- 2020-04-30 PL PL20798924.5T patent/PL3964510T3/pl unknown
- 2020-04-30 SM SM20240303T patent/SMT202400303T1/it unknown
- 2020-04-30 FI FIEP20798924.5T patent/FI3964510T3/fi active
- 2020-04-30 ES ES20798924T patent/ES2984617T3/es active Active
- 2020-04-30 JP JP2021564588A patent/JP7582970B2/ja active Active
- 2020-04-30 DK DK20798924.5T patent/DK3964510T3/da active
- 2020-04-30 BR BR112021021230A patent/BR112021021230A8/pt unknown
- 2020-04-30 CA CA3138240A patent/CA3138240C/en active Active
- 2020-04-30 HU HUE20798924A patent/HUE068061T2/hu unknown
- 2020-04-30 LT LTEPPCT/CN2020/088451T patent/LT3964510T/lt unknown
- 2020-04-30 SG SG11202111315XA patent/SG11202111315XA/en unknown
- 2020-04-30 RS RS20240816A patent/RS65747B1/sr unknown
-
2021
- 2021-10-21 IL IL287472A patent/IL287472A/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008133866A1 (en) * | 2007-04-25 | 2008-11-06 | Merck & Co., Inc. | Polymorph of dihydropyrazolopyrimidinone derivative as weel kinase.inhibitor |
| CN108623615A (zh) * | 2017-03-23 | 2018-10-09 | 上海迪诺医药科技有限公司 | 吡唑[3,4-d]嘧啶-3-酮的大环衍生物、其药物组合物及应用 |
| WO2019085933A1 (zh) * | 2017-11-01 | 2019-05-09 | 南京明德新药研发股份有限公司 | 作为Wee1抑制剂的大环类化合物及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2984617T3 (es) | 2024-10-30 |
| SG11202111315XA (en) | 2021-11-29 |
| CA3138240C (en) | 2025-04-01 |
| BR112021021230A2 (https=) | 2021-12-21 |
| RS65747B1 (sr) | 2024-08-30 |
| US12291536B2 (en) | 2025-05-06 |
| SI3964510T1 (sl) | 2024-10-30 |
| BR112021021230A8 (pt) | 2023-04-25 |
| IL287472A (en) | 2021-12-01 |
| PT3964510T (pt) | 2024-07-29 |
| CN113784968A (zh) | 2021-12-10 |
| PL3964510T3 (pl) | 2024-08-19 |
| CN113784968B (zh) | 2024-03-15 |
| HRP20241008T1 (hr) | 2024-11-08 |
| JP2022530812A (ja) | 2022-07-01 |
| HUE068061T2 (hu) | 2024-12-28 |
| SMT202400303T1 (it) | 2024-09-16 |
| EP3964510A1 (en) | 2022-03-09 |
| FI3964510T3 (fi) | 2024-07-24 |
| EP3964510B1 (en) | 2024-07-03 |
| EP3964510A4 (en) | 2023-04-26 |
| JP7582970B2 (ja) | 2024-11-13 |
| US20220220120A1 (en) | 2022-07-14 |
| AU2020266956A1 (en) | 2021-10-28 |
| DK3964510T3 (da) | 2024-07-29 |
| CA3138240A1 (en) | 2020-11-05 |
| WO2020221358A1 (zh) | 2020-11-05 |
| LT3964510T (lt) | 2024-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020266956B2 (en) | Crystal form of Wee1 inhibitor compound and use thereof | |
| US12479839B2 (en) | Crystalline form of ATR inhibitor and use thereof | |
| CA3170068A1 (en) | Spiro ring-containing quinazoline compound | |
| EP2985277A1 (en) | Dipyrromethene crystal and method for manufacturing same | |
| JP2018515581A (ja) | Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物 | |
| CN111253370B (zh) | N-多取代吡啶-2-氨基嘧啶类衍生物及用途 | |
| RU2842334C2 (ru) | Кристаллическая форма ингибирующего wee1 соединения и ее применение | |
| KR20250154490A (ko) | 방향족 아미드 유도체, 이의 제조 방법, 및 그의 용도 | |
| EP4023648A1 (en) | Crystal of carcinogenic fused kinase inhibitor and applications thereof | |
| HK40060045A (en) | Crystal form of wee1 inhibitor compound and use thereof | |
| RU2832707C2 (ru) | Кристаллическая форма ингибитора atr и ее применение | |
| WO2020219587A1 (en) | Pharmaceutical compounds and therapeutic methods | |
| JP7762460B2 (ja) | １Ｈ－ピロロ［２，３－ｃ］ピリジン系化合物の結晶形及びその製造方法 | |
| EP3958833A1 (en) | Pharmaceutical compounds and therapeutic methods | |
| WO2020224585A1 (zh) | 一种mTORC1/2双激酶活性抑制剂的盐型、晶型及其制备方法 | |
| HK40060045B (zh) | Wee1抑制剂化合物的晶型及其应用 | |
| RU2783243C2 (ru) | Макроциклическое соединение, выполняющее функции ингибитора wee1, и варианты его применения | |
| HK40074313B (zh) | 一种atr抑制剂的晶型及其应用 | |
| EA049096B1 (ru) | Кристаллическая форма фторзамещенного соединения пиридопиразола и способ ее получения | |
| HK40074313A (en) | Crystalline form of atr inhibitor and use thereof | |
| BR112020008664B1 (pt) | Composto macrocíclico que atua como inibidor de wee1 e aplicações do mesmo | |
| HK1241358A1 (en) | Crystal of (s)-1-(2-hydroxyethyl)-4-methyl-n- [4-(methylsulfonyl)phenyl]-5-[2-(trifluoromethyl)phenyl]- 1h-pyrrole-3-carboxamide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: WUXI BIOCITY BIOPHARMACEUTICS CO., LTD. Free format text: FORMER APPLICANT(S): SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT CO., LTD. |
|
| FGA | Letters patent sealed or granted (standard patent) |